Abstract: Methods, devices and systems for analyzing precious samples of cells, including single cells are provided. The methods, devices, and systems in various embodiments of the invention are used to assess genomic heterogeneity, which has been recognized as a central feature of many cancers and plays a critical role in disease initiation, progression, and response to treatment. The methods devices and systems are also used to analyze embryonic biopsies for preimplantation genetic diagnosis (PGD). In one embodiment, the devices, systems and methods provided herein allow for the construction of genomic and RNA-seq libraries without a pre-amplification step.

Abstract: Aspects of exemplary fluid disinfection apparatus and methods are described. One aspect is a disinfection apparatus comprising a body comprising a reflecting chamber, a fluid channel to direct a fluid into reflecting chamber, and radiation source positioned to output a disinfecting radiation into the chamber. The body may include an inlet and outlet. For example, the inlet may extend through the body to receive a fluid at a first velocity; the reflecting chamber may extend along an axis of the body; and the outlet may extend through an end of the reflecting chamber to discharge the fluid from the body. In this example, the fluid channel may direct the fluid from the inlet into the reflecting chamber at a second velocity smaller than the first velocity; and the radiation source may be positioned to output the disinfecting radiation into the reflecting chamber toward the outlet.

Abstract: There are provided compounds of Formula I: various compositions thereof and methods for their use in the inhibition of ?-amylase.

Abstract: Methods of making a paper product can comprise forming a substrate from a first furnish that comprises a plurality of pulp fibers, at least partially dewatering the substrate, treating a second furnish that comprises a plurality of surface enhanced pulp fibers (SEPF) at least by adding one or more enzymes to the second furnish, and sizing the dewatered substrate at least by depositing the treated second furnish onto at least one of opposing first and second surfaces of the dewatered substrate. The SEPF can have a length weighted average fiber length that is greater than or equal to 0.20 millimeters (mm) and an average hydrodynamic specific surface area that is greater than or equal to 10 square meters per gram (m2/g).

Abstract: A reactor that operates with ultraviolet light emitting diodes (UV-LEDs) to attain UV photoreactions or UV photo-initiated reaction in a fluid flow for various applications, including water purification. The UV-LED reactor is comprised of a conduit means for passing fluid flow, an ultraviolet light emitting diode (UV-LED), and a radiation-focusing element to focus the UV-LED radiation to the fluid in the longitudinal direction of the conduit. The UV-LED reactor may include photocatalysts or chemical oxidants, which are activated by UV emitted by UV-LEDs for photocatalytic and photo-initiated reactions.

Abstract: The present disclosure relates to processes for treating wastewater such as acid rock drainage. The processes may, for example, comprise subjecting the wastewater to a microbial fuel cell process, neutralizing the acid with a base comprising calcium to produce an aqueous composition comprising calcium ions and subjecting the aqueous composition comprising calcium ions to a biological precipitation process to precipitate the calcium ions as calcium carbonate.

Abstract: An angular image of a scene may be displayed using a light field display. The light field display may comprise a plurality of projection units. Each of the projections units may comprise an imaging system and an optical system. The imaging system may illuminate pixels of a planar image of the scene. Light corresponding to each of the pixels may be directed towards the optical system. The optical system may comprise first and second lenses for redirecting each light beam corresponding to a pixel in different directions. In some embodiments the first and second lenses form a globe lens. A diffusion system may conceal the optical systems. Additionally, or alternatively, the diffusion system may produce a uniform distribution of light at a plurality of different viewing angles.

Abstract: Provided herein are high-throughput sequencing methods to study the diversity and functionality of lymphocyte receptor chains and pairing of the same. Specifically, the methods provided herein are used to identify with confidence one or more lymphocyte receptor chain pairs in a sample, for example one or more functional chain pairs.

Abstract: Disclosed is a lithium ion battery comprising a lithium anode, a tellurium cathode and a gel polymer electrolyte. The gel polymer electrolyte may comprise a polymer matrix and a lithium compatible salt.

Abstract: A power-factor corrected AC/DC converter has three half-bridge legs, electrically coupled with each other in parallel, each leg having a pair of switches. Each switch of the pair is electrically coupled to the other in series via a respective node that is electrically coupled through an inductor to an AC line. The converter has a fourth half-bridge leg electrically coupled with the other legs to form an electrically parallel circuit. The fourth leg has a pair of switches electrically coupled to each other in series via a fourth node, which is selectively electrically coupleable to a neutral or a second AC line. The converter has a controller that operates the three legs as a 3-channel interleaved AC/DC boost converter and couples the fourth node to the neutral or second AC line if the input is single-phase, and as a 3-phase AC/DC boost converter if the input is three-phase.

Abstract: Devices for treating a bone and methods of inserting such devices into a bone are disclosed. A device for treating a bone may include a flexible tube, a stiffening mechanism and an actuator. The flexible tube has a distal end and a proximal end. The stiffening mechanism within the flexible tube is configured to cause the flexible tube to become rigid. The actuator is configured to cause the stiffening mechanism to cause the flexible tube to become rigid in response to the actuator being actuated.

Abstract: Provided herein are enzymatic compositions for protein O-glycosylation and sialylation, methods and systems associated therewith. In particular, the composition for in vivo sialylation of therapeutic proteins. The composition comprises a polypeptide N-acetylgalactosaminyltransferase; a ?-1,3-galactosyltransferase; an UDP-Glc/GlcNAc 4-epimerase; a disulfide bond isomerase; and an ?-2,3-sialyltransferase or an ?-2,6-sialyltransferase. Furthermore, provided herein are compositions for efficient and complete O-glycosylation and di-sialylation of therapeutic proteins.

Abstract: A system useful for performing ultrasound elastography of organs such as the liver allows efficient and robust data acquisition. The system may be applied to perform real-time, noninvasive ultrasound imaging of the liver in humans. Steady-state, shear wave absolute elastography is used to measure the Young's modulus of the liver tissue. This method involves the use of an external exciter or vibrator to shake the tissue and generate a shear wave. Accurate placement of an ultrasound transducer facilitates measurement of the tissue motion due to the shear wave. The stiffness of tissues in the region being imaged may be computed from the measured tissue motions. The following innovations address both vibrator and transducer placement, as well as some specific methods to ensure adequate wave propagation, in order to obtain accurate and consistent measurements.

Abstract: A compound comprising a prostate specific membrane antigen (PSMA)-targeting moiety of the following formula or of a salt or a solvate thereof. R0 is O or S. Each of R1a, R1b and R1c may be —CO2H, —SO2H, —SO3H, —PO2H, or —PO3H2, for example. R2 may be methylene or a derivative thereof, propylene or a derivative thereof, or a derivative of ethylene, optionally substituted. R3 is a linker. When the PSMA-targeting moiety is linked to a radiolabeling group, the compound may be used as an imaging agent or therapeutic agent for PSMA-expressing diseases/conditions.

Abstract: Disclosed herein are uses of a polypeptide comprising NIMoEsh to treat a disease or condition associated with acute myocardial infarction (AMI) in a subject in need thereof, of a polypeptide comprising NIMoEsh to restore heart function after AMI in a subject in need thereof, of a polypeptide comprising NIMoEsh to reduce or prevent AMI-induced heart function loss in a subject in need thereof, of a polypeptide comprising NIMoEsh to reduce AMI-induced heart tissue infarct in a subject in need thereof, and of a polypeptide comprising NIMoEsh to protect cardiomyocytes against AMI-induced function loss in a subject in need thereof. Disclosed also herein are methods by which such treating, restoring, reducing or preventing, reducing, and/or protecting may be done, and a polypeptide comprising NIMoEsh for use in such treating, restoring, reducing or preventing, reducing, and/or protecting.

Abstract: Methods and devices are provided herein for identifying a cell population comprising an effector cell that exerts an extracellular effect. In one embodiment the method comprises retaining in a microreactor a cell population comprising one or more effector cells, wherein the contents of the microreactor further comprise a readout particle population comprising one or more readout particles, incubating the cell population and the readout particle population within the microreactor, assaying the cell population for the presence of the extracellular effect, wherein the readout particle population or subpopulation thereof provides a direct or indirect readout of the extracellular effect, and determining, based on the results of the assaying step, whether one or more effector cells within the cell population exerts the extracellular effect on the readout particle. If an extracellular effect is measured, the cell population is recovered for further analysis to determine the cell or cells responsible for the effect.

Abstract: Provided are antibodies, and antigen-binding fragments thereof, which specifically bind to an extracellular poor loop of an alpha 1a subunit of L-type voltage gated calcium channel, and related compositions, kits, and methods of use thereof, for instance, administration to a subject in need thereof to modify an immune response, for example, in the treatment of cancer.

Abstract: Compounds having a structure of formula (I), (I-A), (Ia)-(Ie), (A)-(E), and (II) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of disorders including prostate cancer are also provided.

Abstract: Methods for in situ measurement of an oxidation reduction potential (ORP) and pH of a solution comprising iron are provided. The methods comprise measuring a kinetic parameter at an electrode surface of an electrode system comprising a working electrode, a counter electrode and a pseudo-reference electrode, wherein the kinetic parameter is associated with ferric reduction or both ferric reduction and ferrous oxidation and comparing the kinetic parameter to calibration data for the electrode system to determine the ORP and pH of the solution. Also provided are apparatus and systems for in situ measurement of an ORP and pH of a solution comprising iron. The apparatus and systems comprise an electrode system comprising a working electrode, a counter electrode and a pseudo-reference electrode and a detector for measuring a kinetic parameter at an electrode surface of the electrode system.

Abstract: Provided herein are compositions, method and uses for modulating MCT4 activity or for the treatment of cancer. The compositions comprise antisense oligonucleotides (ASO) for administration to a cancer cell, wherein the cancer cell may be characterized by elevated expression of MCT4. The cancer may be selected from one or more of: prostate cancer; renal cell carcinoma; breast cancer; cervical cancer; liver cancer; bladder cancer; and small cell lung cancer pr. The prostate cancer may be castration-resistant prostate cancer (CRPC).